Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness

Summary

Science Corporation received CE mark under the EU Medical Device Regulation from DEKRA and launched commercial availability of its PRIMA subretinal photovoltaic BCI implant across 30 European countries. Clinical trials showed 80% of patients achieved meaningful visual acuity gains and 84% regained the ability to read letters, numbers and words. First commercial implants are expected soon in Germany, marking the first CE-marked BCI for restoration of detailed form vision in geographic atrophy due to AMD.